Ugur Sahin

New Capabilities

As of July 2026: Rebalancing cancer vaccine portfolio following BNT111 exit; focusing BioNTech resources on BNT113 and BNT116

Metastatic breast cancer typically kills most patients within five years. A small group of women vaccinated in a Duke University clinical trial two decades ago have defied that prognosis entirely; all remain alive today. Researchers found these survivors still carry specialized immune cells that recognize their cancer, offering a model for why some therapeutic vaccines produce lasting results.

Updated Jul 9